Dr. Montalban led a study that proves the efficacy of a drug in primary progressive multiple sclerosis
The New Journal of Medicine has published the positive results of Ocrelizumab in the treatment of primary progressive multiple sclerosis (PPMS). Dr. Xavier Montalban, head of the Service of Neuroimmunology of Vall d’Hebron and director of Cemcat, is the corresponding author of this article and leads the Scientific Board of the phase III clinical trial ORATORIO that has risen out these results. The Sclerosis Multiple Centre of Catalonia (known as Cemcat in Catalan) has participated in this clinical trial.
